Dako to Collaborate with Merck
News Jan 09, 2014
Dako announce today it has entered into a master framework agreement with Merck to develop companion diagnostic tests for oncology drugs currently in Merck’s development pipeline.
"Dako is relentless in its commitment to fighting cancer, together with our customers and pharma partners," said Jacob Thaysen, vice president and general manager for Agilent's Diagnostics and Genomics business. "With Dako’s wide experience in companion diagnostics and its expanded playing field as part of Agilent’s Life Sciences and Diagnostics Group, I see great potential in this new agreement. I warmly welcome Merck as our new partner."
The market for companion diagnostics is steadily growing, as personalized medicine may improve patient care and manage healthcare costs by targeting treatments to individuals more likely to benefit from specific therapies.
Dako collaborates with many top-tier pharma companies to develop companion diagnostics, with a record of successful long-term partnerships with companies such as Bristol-Myers Squibb and Genentech, a member of the Roche Group. Dako continues to attract new partners, most recently Eli Lilly, Pfizer and now Merck.
The financial terms of the master framework agreement were not disclosed.
Research Team Discovers Compound that Stops Cancer From SpreadingNews
Using a mouse model, OHSU physician-scientists lead effort to hone a drug that inhibits cancer cells from spreading to other areas in the body.READ MORE
Mechanism Controlling Multiple Sclerosis Risk IdentifiedNews
Researchers at Karolinska Institutet have now discovered a new mechanism of a major risk gene for multiple sclerosis (MS) that triggers disease through so-called epigenetic regulation. They also found a protective genetic variant that reduces the risk for MS through the same mechanism.
Synthetic DNA Shuffling Enzyme Outpaces Natural CounterpartNews
A new synthetic enzyme, crafted from DNA rather than protein, flips lipid molecules within the cell membrane, triggering a signal pathway that could be harnessed to induce cell death in cancer cells. Researchers say their lipid-scrambling DNA enzyme is the first in its class to outperform naturally occurring enzymes – and does so by three orders of magnitudeREAD MORE